Home » Bortezomib Combo Effective in Advanced Follicular Lymphoma

Bortezomib Combo Effective in Advanced Follicular Lymphoma

August 2, 2011

Bortezomib, given in combination with rituximab, cyclophosphamide, vincristine and prednisone (BR-CVP), is feasible for treating patients with advanced-stage follicular lymphoma.
DoctorsLounge

10Mar
FDA Drug GMP Facility Inspections During the Pandemic
16Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06Apr
Medical Device Cybersecurity: Understand the Latest Developments

Bortezomib Combo Effective in Advanced Follicular Lymphoma

Upcoming Events

FDA Drug GMP Facility Inspections During the Pandemic

Pharmaceutical Naming Regulation: Understanding the Latest Developments

Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Abbott Gets FDA EUA for COVID-19 IgG Antibody Test

In $1.55 Billion Deal, Perrigo Sells Off Generic Drug Business

Turkish Researchers Downgrade Sinovac’s COVID-19 Vaccine Efficacy Rate

Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

The Revised ICH E8: A Guide to New Clinical Trial Requirements